Joe Vruwink's questions to Certara Inc (CERT) leadership • Q2 2025
Question
Joe Vruwink of Baird asked for clarification on whether the multi-billion dollar addressable market for New Approach Methodologies (NAMs) is incremental to the existing biosimulation TAM and sought Certara's interpretation of customer preferences between PBPK and QSP for NAMs.
Answer
CFO John Gallagher confirmed the NAMs opportunity is an additional market. He also noted that QSP is a high-growth area and a key beneficiary of the NAMs trend. CEO William Feehery added that PBPK and QSP are often closely linked, and since QSP is a newer branch of model-informed drug development, the survey results showing lower QSP adoption were not concerning.